A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial by Sekimizu, Masahiro et al.
S tandard treatment for recurrent or refractory ana-plastic lymphoma kinase (ALK)-positive anaplastic 
large cell lymphoma (ALCL) has not been established.  
Various treatments,  including hematopoietic cell trans-
plantation,  have been performed,  but the prognosis of 
conventional chemotherapy-resistant patients is partic-
ularly poor.  ALCL accounts for approximately 10-15% 
of children with non-Hodgkin lymphoma (NHL) and 
1-2% of adult patients with NHL.  Since the number of 
adult patients with NHL has been reported as 17,000 
per year in Japan <National Cancer Center for Cancer 
Control and Information Services.  http://ganjoho.ncc.
go.jp/public/index.html (In Japanese).  (Accessed October 
4,  2017.)>,  the number of adult patients with ALCL is 
estimated to be 170 to 340 per year.  The incidence of 
pediatric ALCL in Japan is reported as approximately 
20 cases per year.  <National Center for Child Health 
and Development.  https://www.ncchd.go.jp/hospital/
sickness/children/lymphoma.html (In Japanese) 
(Accessed March 15,  2018.)> In children and adoles-
cents,  more than 90% of cases are ALK-positive [1] 
compared to only 40-50% of adult patients [2].  Since the 
event-free survival (EFS) rate of ALK-positive ALCL is 
about 70% for both adults and children,  the incidence 
of relapsed/refractory cases is estimated to be 20% to 
30%.  From the above,  it is estimated that the number of 
ALK-ALCL patients with relapsed/refractory disease is 
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20 to 50 per year.
There is no standard treatment for recurrent or 
refractory neuroblastoma,  and this is a serious disease 
with an unfavorable prognosis; therefore,  new drugs 
should be promptly developed.  There is also no stan-
dard established treatment for recurrent or refractory 
ALK-positive ALCL.  Crizotinib is a selective adenosine 
triphosphate (ATP)-competitive small molecule oral 
inhibitor of the anaplastic lymphoma kinase (ALK),  
c-Met/hepatocyte growth factor receptor (HGFR),  and 
ROS1 receptor tyrosine kinases and their oncogenic 
variants (e.g.,  c-Met/HGFR mutations and ALK or 
ROS1 fusion proteins).  Although clinical studies in the 
United States have demonstrated the tolerability and 
safety of crizotinib in childhood patients with malig-
nant neoplasms [3],  there have been no clinical trials in 
Japan investigating the safety and efficacy of crizotinib 
in young Japanese patients.  Thus the appropriate dose 
for young Japanese patients is unclear.  We therefore 
planned an investigator-initiated phase 1/2 study to 
examine the tolerability and safety of this drug in 
Japanese patients with recurrent/refractory ALK-
positive ALCL or recurrent/refractory neuroblastoma 
(phase I) and its efficacy in Japanese patients with 
recurrent/refractory ALK-positive ALCL (phase II).  
Trial design. This is a multicenter,  single-arm,  
open label,  phase I dose-escalation study for ALCL and 
neuroblastoma followed by a phase II study.  This study 
has been registered in the Clinical Trial Registry 
(UMIN000028075).  The trial was approved by the 
institutional review boards of each participating institu-
tion.  Since optimal treatment for recurrent/refractory 
ALK-positive ALCL has not been established,  there is 
no adequate control group for this study.  Therefore,  the 
phase II is a single-arm,  open label study.  The number 
of patients with recurrent/refractory ALK-positive 
ALCL/neuroblastoma is limited; therefore,  a multi-
center study was designed.  Since the upper age limit 
was set as 21 years old in the previous report of an over-
seas clinical trial (ADVL 0912),  we adopted the same 
setting in this trial for purposes of safety.
Endpoints
In the phase I,  the primary endpoints are dose-lim-
iting toxicity (DLT) and adverse events,  while the sec-
ondary endpoints are pharmacokinetics and response.  
In the phase II,  the primary endpoint is the response 
rate evaluated by the Central Evaluation Committee,  
while the secondary endpoints are the complete remis-
sion (CR) rate,  duration of response,  progression-free 
survival (PFS),  event-free survival (EFS),  and adverse 
events.
In the analysis set,  the proportion of patients with 
CR or partial response as the best response is regarded 
as the response rate.  In addition,  the proportion of 
patients with CR as the best response is regarded as the 
CR rate.
The duration of response refers to a period from the 
first day of CR or PR evaluation until the first day of PD 
evaluation or day of death (earlier).  The patients who 
continued study participation until the analysis without 
showing PD,  those who received anti-tumor treatments 
other than the test treatment and stem cell transplanta-
tion,  and those excluded from this study before CR or 
PR evaluation were censored at the last day of image 
assessment.
The PFS refers to a period from the start of treat-
ment (Day 1 of Cycle 1) until the first day of PD evalua-
tion or day of death (earlier).  The patients who contin-
ued study participation until the analysis without 
showing PD,  those who received anti-tumor treatments 
other than the test treatment,  and those excluded from 
this study before CR or PR evaluation were censored at 
the last day of image assessment.
The EFS refers to a period from the start of treat-
ment (Day 1 of Cycle 1) until the first day of PD evalua-
tion,  the day of toxicity-related permanent test-treat-
ment discontinuation,  the day of permanent 
test-treatment discontinuation based on the patient’s 
will,  the first day of a new treatment other than stem 
cell transplantation in the absence of PD verification,  
the day of secondary-cancer onset,  or the day of death 
(earlier).  The patients who continued study participa-
tion until the analysis without showing PD,  those who 
underwent stem cell transplantation,  and those 
excluded from this study before CR or PR evaluation,  
are censored at the last day of image assessment.
Eligibility Criteria
Inclusion criteria
Phase I:
 1)  Aged 1 to 21 years upon provision of informed con-
sent by the patient and/or their guardian.
 2)  Histologically confirmed recurrent/refractory 
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ALK-positive ALCL or recurrent/refractory neuro-
blastoma at the initial diagnosis or relapse.  
 3)  Capable of providing histopathology tissues or slides 
of lymphoma for central review.
 4)  Measurable or evaluable disease.
 5)  A Karnofsky performance status of 50% to 100% for 
those aged ≥ 17 years and a Lansky performance 
status of 50% to 100% for those aged ≤ 16 years.
 6)  Full recovery from the acute toxic effects of all prior 
anti-cancer therapy,  except for alopecia.
 7)  Fulfillment of the organ function requirement 
defined in the protocol.  
Phase II:
 1)  Aged 1 to 21 years upon provision of informed con-
sent by the patient and/or their guardian.
 2)  Histologically confirmed recurrent/refractory 
ALK-positive ALCL at the initial diagnosis or 
relapse.
 3)  Capable of providing histopathology tissues or slides 
of lymphoma for central review.
 4)  Measurable disease.
 5)  A Karnofsky performance status of 50% to 100% for 
those aged ≥ 17 years and a Lansky performance 
status of 50% to 100% for those aged ≤ 16 years.  
 6)  Full recovery from the acute toxic effects of all prior 
anti-cancer therapy,  except for alopecia.
 7)  Fulfillment of the organ function requirement 
defined in the protocol.
Exclusion criteria
Phase I/II:
 1)  Central nervous system disease.
 2)  Primary cutaneous ALCL.
 3)  Pregnant or breast-feeding women.  
 4)  Reproductive potential together with refusal of an 
effective contraception method.
 5)  Any of the following concomitant medications:
 - Therapeutic corticosteroids for lymphoma
 -Other investigational drugs 
 -Anticancer agents 
 -CYP3A4 substrates with a narrow therapeutic 
index (e.g.,  pimozide,  aripiprazole,  triazolam,  
ergotamine,  or halofantrine)
 -Strong CYP3A4 inhibitors (e.g.,  ketoconazole,  
itraconazole,  miconazole,  clarithromycin,  eryth-
romycin,  ritonavir,  indinavir,  nelfinavir,  saquina-
vir,  amprenavir,  delavirdine,  nefazodone,  dilti-
azem,  verapamil,  or grapefruit juice)
 - Strong CYP3A4 inducers (e.g.,  carbamazepine,  
phenobarbital,  phenytoin,  rifabutin,  rifampin,  
tipranavir,  ritonavir,  or St. John’s wort)
 6)  Current interstitial fibrosis or interstitial lung dis-
ease or a known history of either condition.  
 7)  Current myocardial infarction or cerebrovascular 
disorder or a known history of either condition.
 8)  An uncontrolled infectious disease.
 9)  Potential inability to comply with the safety moni-
toring requirements of the study in the opinion of 
the investigator.
10)  Inability to swallow capsules or oral solution.  
Patients receiving an oral solution using a feeding 
tube are allowed.
Treatment Methods
Interventions. Crizotinib is given orally twice a 
day.  A cycle of therapy is considered to be 28 days.  The 
main analysis is performed after 6 cycles in Phase I and 
12 cycles in Phase II.  The dose of crizotinib should be 
adjusted with the body surface area determined based 
on the height and body weight.  As a rule,  only in the 
first cycle,  crizotinib should be administered with hos-
pitalization.
Dose. A phase I clinical study involving children 
with solid tumors in the United States (ADVL0912) [4] 
demonstrated the tolerability of this drug at a dose of 
280 mg/m2 administered twice a day.  Further,  there 
was no appearance of DLT at any dose,  with the excep-
tion of brain tumor-associated DLT at 215 mg/m2.  
Based on these data,  the initial dose of this drug might 
have been established as 280 mg/m2 in this trial,  since 
we did not enroll brain tumor patients,  but this dose 
exceeds the body surface area-converted value (165 mg/m2) 
of the dose approved for Japanese adults.  Therefore,  the 
initial dose was established as 165 mg/m2,  in consider-
ation of safety,  and two-stage dosimetry was adopted.
The dose of crizotinib should be adjusted with the 
body surface area determined based on the height and 
body weight measured within 1 week before the start of 
a cycle.  Even when subjects are obese or thin,  correc-
tion with the standard body weight will not be per-
formed.  Even if there are changes in the height or body 
weight after the start of administration,  dose regulation 
by the re-calculation of the body surface area will not be 
conducted during the cycle.  The body surface area 
should be calculated using the following formula (the 
height is expressed as a value obtained by rounding off 
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the first decimal place,  and the body weight is 
expressed as a value obtained by rounding off the sec-
ond decimal place):
body surface area (m2) = square root of {height (cm) 
x body weight (kg)/3,600} (values are rounded off to 
two decimal places).
 1) Phase I (See Tables 1-3 for details. )
•Cohort 1 (dose level: 0): 165 mg/m2/dose
・Cohort 2 (dose level: + 1): 280 mg/m2/dose
・Reduced dose level from + 1: 215 mg/m2/dose
 2) Phase II
The recommended doses for the phase II established 
in the phase I should be adopted.  (See DLT assessment/
recommendation doses for the phase II.)
DLT assessment/recommendation doses for the 
phase II. DLT should be evaluated from Day 1 of 
Cycle 1 until Day 28 in the phase I.  DLT is defined as 
the following events possibly/probably/definitely related 
to this drug.  The grade of DLT should be assessed 
according to the Common Terminology Criteria for 
Adverse Events v4.03.
 1) Non-hematological DLT
i.  All Grade 4 non-hematological toxicities.
ii.   All Grade 3 non-hematological toxicities,  excluding 
the following:
 -Grade 3 nausea/vomiting persisting for < 3 days.  
 -Grade 3 abnormal alanine aminotransferase/
aspartate aminotransferase values that recover to 
the baseline during a 14-day period of dose inter-
ruption and do not recur after the resumption of 
administration.
 -Grade 3 fever/infection persisting for < 5 days.
 -Grade 3 hypophosphatemia/-kalemia/-calce-
mia/-magnesemia responding to oral supplemen-
tation.  
iii.  Grade 2 allergic reactions requiring temporal dose 
interruption are not regarded as DLT.
iv.  All Grade 2 non-hematological toxicities persisting 
for ≥ 7 days and requiring temporal dose interrup-
tion due to intolerance.
v.  All adverse events requiring temporal dose interrup-
tion for ≥ 15 days or that recur after the resumption 
of drug administration.
2) Hematological DLT
Grade 4 peripheral blood neutropenia and Grade 4 
thrombocytopenia.
In this trial,  3 to 6 patients will be assigned to each 
cohort.  The coordinating investigator must assess the 
tolerability of the dose/administration method based on 
the incidence of DLT during the DLT assessment 
period,  and evaluate whether switching to the next 
cohort or Phase II is possible.  If none of the 3 patients 
in Cohort 1 experience DLT,  the dose/administration 
method should be evaluated as tolerable,  and escalation 
to Cohort 2 should be performed.  If 1 patient experi-
ences DLT,  3 more patients should be added to the same 
cohort to examine a total of 6 patients.  If ≤ 1 of the 6 
patients experiences DLT,  the dose/administration 
method should be evaluated as tolerable,  and escalation 
to Cohort 2 should be performed.  However,  if 2 or 
more patients experience DLT,  the coordinating inves-
tigator must determine the tolerability of the dose/
administration method and whether escalation to 
Cohort 2 is possible in conference with the Efficacy/
434 Sekimizu et al. Acta Med.  Okayama　Vol.  72,  No.  4
Table 2　 Dose assignment: Dose Level+1,  crizotinib 280 mg/
m2/dose BID
Dose assignment: Dose Level +1,  crizotinib 280 mg/m2/dose BID
Body surface 
area (m2)
Total daily 
dose (mg/day)
Capsule formulation
(150,  200,  250 mg)
Oral solution
(25 mg/ml)
mg/dose,  PO,  BID ml/dose,  PO,  BID
0.30-0.40 200 - - 4 4
0.41-0.49 250 - - 5 5
0.50-0.58 300 150 150 6 6
0.59-0.67 350 200 150 8 6
0.68-0.80 400 200 200 8 8
0.81-0.98 500 250 250 10 10
0.99-1.16 600 300 300 12 12
1.17-1.33 700 350 350 14 14
1.34-1.51 800 400 400 16 16
1.52-1.69 900 450 450 18 18
1.70-1.87 1,000 500 500 20 20
1.88- 1,100 550 550 22 22
Table 1　 Dose assignment: Dose Level 0,  crizotinib 165 mg/
m2/dose BID
Dose assignment: Dose Level 0,  crizotinib 165 mg/m2/dose BID
Body surface
area (m2)
Total daily 
dose (mg/day)
Capsule formulation
(150,  200,  250 mg)
Oral solution
(25 mg/ml)
mg/dose,  PO,  BID ml/dose,  PO,  BID
0.30-0.38 100 - - 2 2
0.39-0.53 150 - - 3 3
0.54-0.68 200 - - 4 4
0.69-0.83 250 - - 5 5
0.84-0.98 300 150 150 6 6
0.99-1.13 350 200 150 8 6
1.14-1.28 400 200 200 8 8
1.29-1.43 450 250 200 10 8
1.44-1.66 500 250 250 10 10
1.67- 600 300 300 12 12
Safety Evaluation Committee.  If none of the 3 patients 
in Cohort 2 experience DLT,  the dose/administration 
method should be evaluated as tolerable,  and Dose 
level + 1 should be defined as the recommended dose for 
Phase II.  If 1 of the 3 patients in Cohort 2 experiences 
DLT during the DLT assessment period,  3 patients 
should be added to the same cohort to examine a total 
of 6 patients.  If ≤ 1 patient experiences DLT in Cohort 
2,  Dose level + 1 should be defined as a recommenda-
tion dose for Phase II.  When ≥ 2 patients experience 
DLT in Cohort 2,  Dose level 0 should be defined as a 
recommended dose for the Phase II,  provided that 6 
patients comprise Cohort 1.  When 2 or more patients 
experience DLT in Cohort 2 and 3 patients comprise 
Cohort 1,  3 patients should be added to Cohort 1 and 
Dose level 0 should be defined as the recommended 
dose for Phase II,  provided that ≤ 1 of the 6 patients 
experiences DLT.  If 2 or more patients experience DLT 
in Cohort 2 and 2 or more patients experience DLT in 
Cohort 1,  to which 3 patients were added,  the coordi-
nating investigator must determine the tolerability of the 
dose/administration method in conference with the 
Efficacy/Safety Evaluation Committee.  For switching to 
Phase II,  data on the tolerability/safety from Cohorts 1 
and 2 of this trial must be comprehensively reviewed in 
cooperation with the Efficacy/Safety Evaluation 
Committee.
Efficacy assessment.
1. Neuroblastoma
In this trial,  the modified Response Evaluation 
Criteria in Solid Tumors version 1.1 [5] will be used 
when evaluating the treatment response.  For evaluable 
lesions,  the responses of MIBG-positive lesions must be 
evaluated using the Curie scale [6],  and others should 
be evaluated in the same manner as at baseline.
2. ALCL
In this trial,  the Revised Response Criteria for 
Malignant Lymphoma [7] will be used when evaluating 
the treatment response.
Statistical Considerations
Sample size. The scheduled number of patients to 
be registered is 6-12 in the phase I.  The number of 
patients per cohort was established as 3 to 6 with refer-
ence to the “Guidelines for the clinical assessment of 
antitumor drugs”.  <Pharmaceu tical and Food Safety 
Bureau,  Ministry of Health,  Labour and Welfare.  
https://www.pmda.go.jp/files/000206740.pdf (In 
Japanese).  (Accessed October 4,  2017)>.
The scheduled number of patients to be registered is 
11 in the phase II.  A standard therapy has yet to be 
established for patients with recurrent or refractory 
ALCL.  Past research indicates a long-term survival rate 
of 40-60% for recurrent or refractory ALCL.  < National 
Cancer Center for Cancer Control and Information 
Services.  http://ganjoho.jp/child/cancer/neuroblas-
toma/index.html (In Japanese).  (Accessed October 4,  
2017).> In addition,  the PROPEL trial for recurrent or 
refractory peripheral T-cell lymphoma showed a 35% 
(6/17 cases) objective response rate for ALCL (both 
ALK-positive and -negative) patients using Pralatrexate 
[8].  Referencing these reports,  the threshold response 
rate for purposes of the present trial was determined as 
50%.  Crizotinib showed a response rate of 89% (8/9 
cases) [4] in a trial of pediatric recurrent or refractory 
ALCL patients.  Reported response rates to brentux-
imab vedotin (recombinant) in recurrent or refractory 
ALCL patients were 100% (5/5 cases) in Japan and 86% 
(50/58 cases) overseas [9].  Other studies have reported 
response rates of 80% or higher [10] < National Cancer 
Center for Cancer Control and Information Services.  
http://ganjoho.ncc.go.jp/public/index.html (In 
Japanese).  (Accessed October 4,  2017.)>,  <National 
Comprehensive Cancer Network.  https://www.nccn.
org/professionals/physician_gls/pdf/t-cell.pdf.  
(Accessed July 19,  2017. )>.  We expected that our drug 
would elicit response rates comparable to these drugs,  
and thus set the expected response rate as 85%.  Since a 
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Table 3　 Dose assignment: Reduced dose Level from+1,  crizo-
tinib 215 mg/m2/dose BID
Dose assignment: Reduced Dose Level from+1,  crizotinib 215 mg/m2/dose 
BID
Body surface 
area (m2)
Total daily 
dose (mg/day)
Capsule formulation
(150,  200,  250 mg)
Oral solution
(25 mg/ml)
mg/dose,  PO,  BID ml/dose,  PO,  BID
0.30-0.40 150 - - 3 3
0.41-0.52 200 - - 4 4
0.53-0.63 250 - - 5 5
0.64-0.80 300 150 150 6 6
0.81-0.98 350 200 150 8 6
0.99-1.16 400 200 200 8 8
1.17-1.33 500 250 250 10 10
1.34-1.51 600 300 300 12 12
1.52-1.69 650 350 300 14 12
1.70-1.87 700 350 350 14 14
1.88- 800 400 400 16 16
statistical power of 78% could be obtained using 11 
cases with an alpha level of 0.05 (one-tailed),  the sample 
size was 11.
Statistical analysis.
Analysis set
The Full Analysis Set (FAS) consists of patients reg-
istered in this trial and treated with the investigational 
drug.  However,  cases where it has been found that 
there is a Good Clinical Practice (GCP) violation after 
registration,  and cases which are found to be ineligible 
after registration are excluded.  In the FAS,  a popula-
tion without serious protocol violations,  meeting the 
protocol regulations,  is regarded as a Per Protocol Set.  
In this study,  the FAS is the primary analysis set of effi-
cacy.  Patients registered in this trial and treated with the 
investigational drug at least once are regarded as the 
safety analysis set.
Patients to be analyzed for DLT are defined as follows:
•Patients with 1 or more episode of DLT during the DLT 
assessment period (from Day 1 of Cycle 1 until the 
time of administration on Day 1 of Cycle 2).
or
•Those to whom a specific dose (≥ 75%) of crizotinib 
was administered in Cycle 1 and in whom observa-
tion during the DLT assessment period was com-
pleted.
Patients,  registered in this trial,  with pharmacoki-
netic data at least one are regarded as a population to be 
analyzed for the pharmacokinetics.
The response rate,  the CR rate and their 90% confi-
dence intervals will be calculated.
To estimate the duration of response,  PFS,  and EFS,  
the Kaplan-Meier method will be used.  The 90% confi-
dence interval of these values will be calculated using 
Greenwood’s formula.  The incidence of DLT will be 
calculated with respect to the dose levels.  The incidence 
of adverse events/reactions to the investigational drug 
will be calculated with respect to the events,  grade,  and 
severity.  
Discussion
This is an exploratory study pursuant to the perfor-
mance of a multinational study.  The objectives of this 
study are to evaluate the tolerability and safety of this 
drug in Japanese patients with recurrent/refractory 
ALK-positive ALCL or recurrent/refractory neuroblas-
toma (phase I) and its efficacy in Japanese patients with 
recurrent/refractory ALK-positive ALCL (phase II).
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